Founded in 2010, BioPharmX Corporation (NASDAQ:BPMX) is headquartered in Menlo Park, California, USA, with 27 full-time employees. It is a specialty biopharmaceutical company that develops and commercializes new prescription and over-the-counter drugs (OTC) for the treatment of skin diseases and women’s health markets. product.
BioPharmX Corporation (BPMX):
BioPharmX is a professional pharmaceutical company focusing on the skin disease market. The company’s focus is on developing products for the treatment of chronic skin diseases. These markets currently have unmet medical needs, or the current treatments and methods are not optimal.
BioPharmX Corporation’s strategy is to bring new products to the market by determining the best delivery mechanism and/or alternative applications for FDA-approved or fully characterized active pharmaceutical ingredients (API). The company’s goal is to reduce the time normally associated with new product development by using active ingredients with proven safety and using accelerated regulatory approaches (such as the Federal Food, Drug and Cosmetic Act 505(b)(2) Section). Costs and risks.
BioPharmX Corporation provides VI2OLET (commercial stage), an OTC molecular iodine dietary supplement that can solve periodic breast discomfort and relieve the symptoms of fibrocystic breast disease (FBC).
BioPharmX’s clinical stage candidate products include:
- BPX01, a topical antibiotic gel, has completed phase II clinical trials for the treatment of acne inflammatory lesions;
- BPX04, a topical antibiotic, is in the Phase II pre-feasibility study for the treatment of inflammatory lesions in rosacea;
- BPX02, a candidate product in the development stage for cosmetic and dermatological applications;
- BPX03, a molecular iodine tablet, has completed a phase III pre-clinical trial for the treatment of periodic breast pain associated with FBC and circulatory mammary pain.
BioPharmX Corporation serves pharmaceutical companies, clinicians, including obstetricians and gynecologists, dermatologists and general practitioners; and serves retail customers through retail channels and/or pharmacies.
BioPharmX signed a cooperation and licensing agreement with Iogen LLC to develop molecular iodine formulations; and signed a collaboration and supply agreement with NuTech Medical, Inc. ( acquired by Organogenesis Holdings Inc. in 2017 ) to develop products in the field of dermatology.